What are the most common adverse effects reported with Talzenna in clinical studies?

In pooled clinical studies of Talzenna monotherapy and Talzenna combined with enzalutamide, the most common adverse reactions (≥20%) were anaemia (55.6%), fatigue (52.5%), nausea (35.8%), neutropenia (30.3%), thrombocytopenia (25.2%) and decreased appetite (21.1%).